Veterinary medicines regulations in Great Britain, NI and EU
Veterinary medicines rules differ in GB, Northern Ireland and the EU. Check authorisation routes, CVMP opinions, NI supply and withdrawal periods.
Veterinary medicines regulations differ between Great Britain, Northern Ireland and the EU. Great Britain uses the Veterinary Medicines Regulations 2013, as amended. Northern Ireland follows EU veterinary medicines legislation alongside relevant domestic provisions. The Veterinary Medicines Directorate (VMD) explains the territorial split.
For regulatory teams, the first check is the destination market. A GB marketing authorisation does not cover Northern Ireland. An EU centralised authorisation includes Northern Ireland, but not GB. A positive scientific opinion from EMA's veterinary committee is not itself permission to market a medicine. VMD's authorisation guidance sets out the routes and their coverage.
Which veterinary medicines regulations apply?
The position as at 7 November 2026 is:
| Market | Main framework | Practical distinction |
|---|---|---|
| Great Britain | Veterinary Medicines Regulations 2013, as amended, including the 2024 amendments | GB covers England, Wales and Scotland. VMD assesses GB national authorisations. |
| Northern Ireland | EU veterinary medicines legislation under the Windsor Framework, with relevant domestic provisions | Check NI-specific authorisation and supply requirements. A GB authorisation alone is insufficient. |
| EU | Regulation (EU) 2019/6 | The authorisation route determines which markets the authorisation covers. |
Sources: VMD regulations guidance, VMD marketing-authorisation guidance and Regulation (EU) 2019/6.
The Veterinary Medicines Regulations 2013 came into force on 1 October 2013. Their scope includes manufacture, authorisation, possession, distribution, use and post-authorisation surveillance. The 2024 amending regulations took effect on 17 May 2024 and extend to England, Wales and Scotland. Refer to the Veterinary Medicines Regulations 2013, as amended, rather than "VMR 2024".
The EU veterinary medicinal products regulation, Regulation (EU) 2019/6, has applied since 28 January 2022. January 2026 brought changes to NI supply arrangements, not the first application of that regulation. Medicated feed has a separate EU framework under Regulation 2019/4, as VMD's overview explains.
Marketing authorisations and the CVMP's role
Select the route by territory and the product's existing authorisation status. Under VMD's guidance, the main distinctions are:
- A GB national application goes to VMD for assessment under the VMR.
- An NI national application follows EU requirements. This route is available only if the product is not already authorised or under assessment in an EU Member State.
- The decentralised procedure involves simultaneous applications in several Member States for a product without an existing national authorisation. A reference Member State leads assessment. Participating national authorities issue authorisations after agreement.
- Mutual recognition extends recognition of an existing national authorisation to additional participating territories.
- The centralised EU procedure involves EMA scientific evaluation followed by a European Commission authorisation.
NI can participate in coordinated procedures as a concerned member state. It cannot act as the reference Member State. These distinctions matter when choosing the lead authority and intended markets for an application. VMD sets out NI's procedural role.
CVMP means Committee for Veterinary Medicinal Products. It provides scientific evaluations and opinions on centralised applications, variations, safety matters and referrals. It also recommends maximum residue limits. EMA forwards its scientific opinion to the Commission, which grants the centralised marketing authorisation. See EMA's CVMP page and its marketing-authorisation overview.
When reviewing an EMA CVMP opinion, distinguish the scientific recommendation from the Commission decision. Use the official committee page to find CVMP meeting material and committee information. Do not use a meeting summary or scientific guideline as proof that a product has marketing authorisation.
Northern Ireland supply arrangements from January 2026
From 1 January 2026, ordinary authorised supply from GB to NI generally requires an appropriately authorised manufacturer. It also requires batch testing and NI/EU Qualified Person release, with packaging reflecting the relevant legal entity. The marketing authorisation holder must be established in NI or an EU Member State. Specific schemes and exceptions apply, so check the proposed supply route against VMD's NI supply guidance.
Two schemes took effect on 1 January 2026. VMD's supplementary guidance, updated on 5 November 2026, supports checks on their operation.
The Veterinary Medicines Internal Market Scheme, or VMIMS, operates within the prescribing cascade. It removes individual Special Import Certificate requirements for qualifying GB-authorised medicines. Clinical justification and cascade compliance remain necessary. The scheme excludes immunological veterinary medicines, including GB vaccines. It does not provide blanket recognition of GB marketing authorisations.
The Veterinary Medicine Health Situation Scheme, or VMHSS, permits suitable EU-authorised alternatives exceptionally for an animal or public-health situation. It can include EU vaccines and non-prescription medicines. Product-specific permits and conditions apply.
For a supply decision, identify the scheme and its conditions before arranging movement. Check the relevant scheme guidance rather than relying on a general "UK-authorised" description.
Maximum residue limits and withdrawal periods
A maximum residue limit, or MRL, is a permitted residue concentration in food of animal origin. A withdrawal period is the time after final administration before slaughter or collection of food produce. Its purpose is to keep residues within the applicable limits. These are different measures, as EMA's MRL guidance explains.
CVMP recommends EU MRLs, which become legally binding through Commission adoption. An MRL does not authorise a finished veterinary medicine. The EU framework is set out in Regulation (EC) No 470/2009.
NI uses EU MRLs. GB has its own MRL register, retaining relevant pre-end-2020 limits. Applications to establish, extend or change a GB MRL go to VMD. Check the correct register through VMD's MRL guidance.
For cascade use, the prescribing vet must set an appropriate withdrawal period. Do not automatically reuse the authorised period after changing the species, dose, treatment duration or conditions. There is no universal 28-day rule. Use the territorial and food-producing-species sections of VMD's cascade guidance for the applicable requirements.
Antimicrobial rules differ between GB and NI
GB's 2024 antibiotic restrictions prohibit routine use and use to compensate for poor hygiene, husbandry or farm management. They also prohibit growth promotion or increased yield. Prophylaxis is exceptional, where risk is very high and consequences are likely to be severe. VMD explains these restrictions.
Group antibiotic prophylaxis is not absolutely prohibited in GB. It requires recorded justification and a veterinary management review aimed at eliminating future need. EU/NI Article 107 covers antimicrobials, not just antibiotics. It prohibits routine use, compensation for poor husbandry and growth promotion. Antibiotic prophylaxis is limited to an individual animal. Antimicrobial metaphylaxis requires a high risk of group spread and no appropriate alternatives. Compare GB guidance with Article 107 of Regulation 2019/6.
Two EU measures also need attention:
- Implementing Regulation (EU) 2022/1255, applicable since 9 February 2023, reserves listed antimicrobials for human treatment. It prohibits their veterinary use, including relevant human medicines used in animals. This is an EU/NI requirement, not automatically directly applicable GB law.
- Implementing Regulation (EU) 2024/1973, applicable since 8 August 2026, sets antimicrobial-specific cascade conditions under Articles 112 and 113, including testing and use restrictions. It excludes equines and does not cover Article 114 food-producing aquatic-animal use.
The latter act contains exceptions. It does not mean testing is required before every antibiotic treatment. Check the relevant antimicrobial and use against the act itself.
Checks before an authorisation or supply decision
Start with the destination territory and the authorisation's coverage. Then match the supply route and product information to that market. For NI movements, check whether ordinary supply requirements or a specific scheme applies. VMD's authorisation guidance and NI supply guidance are starting points, not a complete legal audit.
For food-producing animals, check MRL status separately from the withdrawal period. For antimicrobials, check the territory-specific restrictions rather than copying a GB assessment into an NI file. The relevant MRL guidance and EU regulation address different parts of that decision.
RegAffairs AI provides a public answer on UK veterinary medicines rules and EU approvals.